Save $$$ on Keflex purchased online

While there are many acne treatment products on the market, most of them tend to be very expensive and don’t give you the natural healthiness that some other alternatives offer. Products like Accutane contain so many chemicals that may be hazardous to your health in one way or another. It’s always a good thing to explore certain alternatives. On many over-the-counter acne medicati…

Strategic Review Results in $100MM Investment by Equity Group Investments;
Experienced Commercial Executive Management Team Appointed;
Preparing for Potential MOXATAG Launch in the First Half of 2009
GERMANTOWN, Md., July 1 /PRNewswire-FirstCall/ — MiddleBrook Pharmaceuticals, Inc. , a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that its Board of …

MiddleBrook Pharmaceuticals Inc., the Germantown-based maker of the antibiotic Keflex, reported fourth-quarter revenue of $10.5 million in fiscal 2007, up 117 percent from $4.8 million the year before. Sales for the fourth quarter were $2.9 million, compared to $1.2 million for the same period in 2006.

…

MiddleBrook Pharmaceuticals Inc., of Germantown, formerly Advancis Pharmaceutical Corp., which develops novel anti-infective products, reported a second-quarter net loss of $9.5 million, or 21 cents per dilute…

As a result of reduced revenue and high expenses associated with the launch of its Keflex 750 mg capsules, Advancis Pharmaceutical Corp., of Germantown, reported a third-quarter net loss of $9.9 million, or 36 cents per diluted share, on revenue of $2.4 million, versus a net loss of $5.9 million, or 20 cents per diluted share, …

As Advancis Pharmaceutical Corp. faces growing losses and regulatory challenges, the Germantown-based drug firm is cutting costs by controlling staff size, freezing most of its development programs and actively seeking a partner for acquisition.
The company, which has only one commercialized product, the antibiotic Keflex, had a net loss of $41.99 million in 2006, compared with a $32.99 million loss for 2005.
Its revenue fo…

Case History:

Wesley, a 7-year-old maleGermon Shephord , was presented because of a nine-month history of hair loss and thickened, greasy skin. The dog was moderately pruritic, but the owner could not recall if pruritus had preceded or followed the appearance of the skin lesions. The dog seemed healthy otherwise. A vinegar and water solution had been used topically as well as selenium sulfide shampoo with minimal improvement. Prednisone was dispensed six months before pres…

The superbugs are here, and your child may be at risk.
Widespread and inappropriate antibiotic use have encouraged the emergence of a “superbug” version of the familiar “Staph,” short for Staphylococcus aureus. Staph is a familiar source of infection, and many children carry the bacteria without symptoms, have mild skin infections such as impetigo, or infected hair follicles (folliculitis). It also causes wound in…

This is a Pediatric Management Problem (PMP) designed to test your problem-solving and decision-making abilities.
Instructions: Read the PMP below. Then outline how you would assess and manage the problem. Finally, compare your rationale and decision to that listed in the shaded area,
Please submit material to: Jean Ivey, DSN, CRNP; Pediatric Nursing Journal; East Holly Avenue/Box 56; Pitman, NJ 08071-0056; (856) 256-2345 (fax)
…

Abstract
Bullous pemphigoid (BP) is an acquired autoimmune disease characterized by subepidermal vesicles and bullae. The etiology for BP is mostly idiopathic with the highest occurrence in elderly patients; however, it is now well-accepted that BP has been triggered by or associated with drug therapy. We present a case of furosemide-induced bullous pemphigoid and review the literature of drug-induced bullous pemphigoid (DIBP).
Introduction

Most Popular
10 Jo…